Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).

Antonio Omuro,Lisa M. DeAngelis,Theodore Karrison,Joe A Bovi,Marc K. Rosenblum,Benjamin W. Corn,Denise D. Correa,Jeffrey S. Wefel,Sanjay Aneja,Christian Grommes,Lauren R. Schaff,Steven E. Waggoner,Enrico C. Lallana,Maria Werner-Wasik,Fabio M. Iwamoto,Timothy J. Robinson,Eric D. Donnelly,Timothy Struve,Minhee Won,Minesh P. Mehta

Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).

2020

2501Background: MTX-based chemoradiotherapy is effective in PCNSL, but carries a risk of severe neurotoxicity (NT), especially in the elderly. In a phase II single arm study, R-MPV-A chemotherapy w...

Keywords:

low dose
Cytarabine
Oncology
Vincristine
Procarbazine
Internal medicine
Methotrexate
Pathology
Rituximab
newly diagnosed
Phases of clinical research
Medicine
Chemoradiotherapy
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations